Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543955 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL10324073 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL28532 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL30277 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL15978095 | 0.91 | CYP3A4 (0.37) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL14067502 | 0.87 | CYP3A4 (0.41) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL9309105 | 0.87 | CYP3A4 (0.41) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL9308091 | 0.87 | CYP3A4 (0.41) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL22088075 | 0.87 | CYP3A4 (0.33) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL9701371 | 0.85 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856738-B1 | PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | QUIM SINTETICA S A (ES) | 2025-03-19 | — | — | EP | claimed |
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | claimed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| WO-2024108774-A1 | METAL-CATALYZED DOUBLE HYDROBORATION OF NITROGEN HETEROCYCLICS | GUANGDONG TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY (CN) | 2024-05-30 | — | — | WO | claimed |
| CN-117447464-A | Method for producing optically active compound | 首日生物制药公司 | 2024-01-26 | — | — | CN | claimed |
| US-11465977-B2 | Process for the preparation of sphingosine-1-phosphate receptor agonist | Química Sintética, S.A. (ES) | 2022-10-11 | — | — | US | claimed |
| US-20220033365-A1 | PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Química Sintética, S.A. (ES) | 2022-02-03 | — | — | US | claimed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | claimed |
| EP-2865446-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | KANTO KAGAKU (JP) | 2021-09-22 | — | — | EP | claimed |
| EP-3856738-A1 | PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | Química Sintética, S.A. (ES) | 2021-08-04 | — | — | EP | claimed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | claimed |
| US-7902110-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | claimed |
| US-20080058522-A1 | Process For The Preparation Of Enantiomerically Enriched Beta Amino Acid Derivatives | MERCK SHARP & DOHME LLC | 2008-03-06 | — | — | US | claimed |
| EP-1735269-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED BETA AMINO ACID DERIVATIVES | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2006030202-A1 | “HETEROGENISED” HOMOGENEOUS CATALYSTS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2006-03-23 | — | — | WO | claimed |
| WO-2005097733-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED BETA AMINO ACID DERIVATIVES | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-6583312-B2 | Catalytic hydrogenation of trimethylpyruvic acid | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-24 | — | — | US | claimed |
| US-20020035271-A1 | Process for preparing oprtically active trimethyllactic acid and its ester | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-21 | — | — | US | claimed |
| EP-1160237-A2 | Method for the preparation of optically active trimethyllactic acid and its esters | BAYER AG (DE) | 2001-12-05 | — | — | EP | claimed |
| US-5627256-A | STABILIZER | BAYER AG (DE) | 1997-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058522-A1 | Process For The Preparation Of Enantiomerically Enriched Beta Amino Acid Derivatives | ATIC, SLC1A5, SLC7A1 | CYP3A4 2844/4885TDP1 4047/4885TAAR1 1231/4885 |
| US-20220033365-A1 | PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | S1PR1, S1PR4, S1PR3 | CYP3A4 1653/4885TDP1 2234/4885TAAR1 241/4885 |
| US-20020035271-A1 | Process for preparing oprtically active trimethyllactic acid and its ester | ME1, OPRK1, OPRM1 | CYP3A4 57/4885TDP1 4552/4885TAAR1 3235/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | CYP3A4 608/4885TDP1 4637/4885TAAR1 4102/4885 |
| US-11465977-B2 | Process for the preparation of sphingosine-1-phosphate receptor agonist | S1PR1, S1PR4, S1PR3 | CYP3A4 1653/4885TDP1 2234/4885TAAR1 241/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | CYP3A4 2504/4885TDP1 3532/4885TAAR1 1186/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | CYP3A4 608/4885TDP1 4637/4885TAAR1 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.